Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances
This article was originally published in The Pink Sheet Daily
Executive Summary
As with Purdue’s Targiniq, agency requires a post-marketing study to determine whether the new morphine/naltrexone formulation actually deters abuse.
You may also be interested in...
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.
OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting
There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.
Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon
Purdue epidemiological studies indicate reformulation of OxyContin had a positive effect on abuse and misuse of the drug, but the company says continued monitoring is needed to assess whether the positive trend continues.